IRVINE, Calif., Aug. 25, 2008 (GLOBE NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO) today announced that it has further extended its international expansion into five additional countries. SenoRx will begin marketing EnCor(r), its vacuum-assisted breast biopsy product, and its GelMark(tm) line of breast biopsy tissue markers through distributors in Australia, Korea, Spain, Portugal and Mexico.
SenoRx is partnering with local in-country distributors who have breast imaging and/or interventional radiology franchises in select markets. SenoRx has previously established partnering relationships with distributors in Austria, Belgium, Denmark, Finland, France, Germany, Iceland, Ireland, Italy, Luxembourg, The Netherlands, Norway, Russia, Sweden, Switzerland, United Kingdom, Hong Kong, Singapore, and Taiwan.
"Our earlier initiatives have delivered encouraging results to date and we see further potential for international sales to grow as a percent of overall revenues over the longer-term," said Lloyd Malchow, SenoRx President and Chief Executive Officer. "Our intention has been to enter additional countries on a step-wise basis to further capitalize on the interest from clinicians in our breast-care products that we see in a number of markets around the world. With the addition of these five new geographic markets, SenoRx will now have a presence in over 20 countries."
EnCor and SenoRx breast tissue biopsy markers have previously received the necessary regulatory clearances in the European Economic Community and in all the countries that SenoRx has established distribution channels, along with several other countries in Asia as well.
About SenoRx
SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(r) vacuum-assisted breast biopsy system and Contura(tm) MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx's field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx has recently launched several of its products through distributors in more than 20 countries outside the U.S. and Canada. The company's line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.
The SenoRx, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3605
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning international sales growth are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause SenoRx's actual results to differ materially from the statements contained herein. Information on potential risk factors that could affect SenoRx's business and its financial results are detailed in its most recent quarterly report on Form 10-Q, as filed with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. SenoRx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events